2 weeks Ago By ABMN Staff
Long Focus Capital Management LLC increased its holdings in Sight Sciences, Inc. ( NASDAQ:SGHT – Free Report ) by 86.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 560,594 shares of the company’s stock after purchasing an additional 260,594 shares during the quarter. Long Focus Capital Management LLC owned 1.13% of Sight Sciences worth $3,739,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the business. Steele Capital Management Inc. acquired a new stake in shares of Sight Sciences during the second quarter valued at approximately $67,000.
State Board of Administration of Florida Retirement System purchased a new stake in shares of Sight Sciences in the first quarter valued at $59,000. The Manufacturers Life Insurance Company purchased a new position in shares of Sight Sciences during the second quarter valued at $95,000. Mirae Asset Global Investments Co.
Ltd. raised its position in Sight Sciences by 51.9% during the first quarter.
Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after buying an additional 9,106 shares during the period.
Finally, American Century Companies Inc. lifted its stake in Sight Sciences by 31.1% in the 2nd quarter.
American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after acquiring an additional 8,527 shares in the last quarter. Institutional investors and hedge funds own 55.
51% of the company’s stock. Wall Street Analysts Forecast Growth Several equities analysts have weighed in on SGHT shares. Citigroup lifted their target price on Sight Sciences from $6.
00 to $6.50 and gave the company a “neutral” rating in a research note on Wednesday, July 10th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd.
Morgan Stanley lifted their target price on shares of Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a research note on Monday, July 15th.
Finally, Lake Street Capital assumed coverage on Sight Sciences in a report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price objective for the company.
Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Sight Sciences has a consensus rating of “Hold” and a consensus price target of $7.25.
Insider Buying and Selling In other news, insider Jeremy B. Hayden sold 5,055 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $6.
21, for a total transaction of $31,391.55. Following the transaction, the insider now owns 163,565 shares in the company, valued at approximately $1,015,738.
65. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website . In other Sight Sciences news, CFO Alison Bauerlein sold 10,497 shares of the business’s stock in a transaction on Tuesday, July 2nd.
The shares were sold at an average price of $6.21, for a total value of $65,186.37.
Following the sale, the chief financial officer now owns 402,685 shares of the company’s stock, valued at approximately $2,500,673.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link .
Also, insider Jeremy B. Hayden sold 5,055 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $6.
21, for a total transaction of $31,391.55. Following the transaction, the insider now owns 163,565 shares of the company’s stock, valued at approximately $1,015,738.
65. The disclosure for this sale can be found here . Over the last quarter, insiders have sold 34,774 shares of company stock valued at $219,243.
28.90% of the stock is owned by company insiders. Sight Sciences Trading Up 2.
2 % Sight Sciences stock opened at $6.57 on Friday. Sight Sciences, Inc.
has a one year low of $1.04 and a one year high of $8.45.
The company’s fifty day moving average price is $6.67 and its two-hundred day moving average price is $6.17.
The company has a debt-to-equity ratio of 0.33, a current ratio of 11.01 and a quick ratio of 10.
50. The company has a market capitalization of $326.90 million, a price-to-earnings ratio of -5.
87 and a beta of 2.72. Sight Sciences ( NASDAQ:SGHT – Get Free Report ) last announced its earnings results on Thursday, August 1st.
The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.
06. The firm had revenue of $21.37 million during the quarter, compared to the consensus estimate of $21.
32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.
90%. During the same quarter in the prior year, the company earned ($0.30) EPS.
On average, analysts forecast that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year. Sight Sciences Company Profile ( Free Report ) Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. See Also Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
